Comparison of anti-hepatitis C virus detection with ELISA assay and RIBA 4 in dialysis patients: our experience.
Hepatitis C virus (HCV) has been demonstrated to be the main cause of non-A, non-B hepatitis and the emergent infectious illness in dialysis units. At present, the anti-HCV 100 ELISA and an immunoblot assay in which 2 new antigens are included, are available. We have tested 110 patients on chronic dialysis with anti-C100 ELISA. Twenty-seven of them were anti-HCV positive. We tested the 27 anti-HCV-positive and 7 anti-HCV-negative patients with the RIBA 4 assay. The results were similar with both test.
Innocenti
M
M
Nephrology Unit, Livorno, Italy.
Mazzoni
A
A
Moretti
A
A
Palla
P
P
D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005069:Evaluation Studies as Topic; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000097:blood*; D018937:Hepatitis C Antibodies; D006801:Humans; D015151:Immunoblotting / Q000379:methods; D006435:Renal Dialysis / Q000009:adverse effects
D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; C078224:anti-C100-3